Adicet Bio Revenue and Competitors

Location

$145.6M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Adicet Bio's estimated annual revenue is currently $42.7M per year.(i)
  • Adicet Bio's estimated revenue per employee is $251,250
  • Adicet Bio's total funding is $145.6M.

Employee Data

  • Adicet Bio has 170 Employees.(i)
  • Adicet Bio grew their employee count by 24% last year.

Adicet Bio's People

NameTitleEmail/Phone
1
VP - Clinical DevelopmentReveal Email/Phone
2
VP, Quality AssuranceReveal Email/Phone
3
VP, Vector Development and QCReveal Email/Phone
4
VP, Cell Therapy Development and ManufacturingReveal Email/Phone
5
VP, Head Human ResourcesReveal Email/Phone
6
VP and Head Clinical OperationsReveal Email/Phone
7
VP BiometricsReveal Email/Phone
8
VP Quality AssuranceReveal Email/Phone
9
VP Program DevelopmentReveal Email/Phone
10
VP, Nonclinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Adicet Bio?

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Adicet Bio raised $51M in series A financing led by OrbiMed Partners, OrbiMed Israel, Novartis Venture Fund and Pontifax.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$145.6M

Total Funding

170

Number of Employees

$42.7M

Revenue (est)

24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Adicet Bio News

2022-04-20 - Adicet Bio Receives FDA Fast Track Designation for Lead ...

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer.

2022-04-20 - Adicet Bio's Lead Candidate ADI-001 Gets FDA Fast Track Designation - Quick Facts

(RTTNews) - Adicet Bio, Inc. (ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta...

2022-04-20 - Adicet Bio stock soars 13% on FDA fast track status for ADI ...

The U.S. Food and Drug Administration (FDA) granted fast track designation to Adicet Bio's (NASDAQ:ACET) lead program ADI-001 to treat...

2021-11-18 - Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors

MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman, M.D. ...

2021-11-18 - Adicet Bio : Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors - Form 8-K

Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors Menlo Park, CA and Boston, MA - November 18, 2021 - Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other d ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.3M171N/AN/A
#2
$47.6M1738%N/A
#3
$31.2M17726%N/A
#4
$27.4M177-12%N/A
#5
$28.6M1794%N/A